Abstract
The alterations of peripheral nerves are relatively frequent in critically ill patients. Such entities can be divided into primary (i.e., those that lead to the patients’ admission to the ICU) or secondary (i.e., those that develop once the patient has been in the ICU as a result of another underlying disease). The Guillain-Barre-Landry syndrome is the most common primary disease while the critical illness myopathy and polyneuropathy are the most commonly seen secondary etiologies. In this brief review we had discussed both of these pathologies and have also included acute intermittent porphyria. We have given an overview of the possible etiology, most common clinical presentation, and treatments of all these entities.
References
Ropper A, Wijdicks E, Truaux B. Guillain-Barre Syndrome. Philadelphia: FA Davis; 1991.
Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 1985;35:1096-104.
Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 1981;9:S31-8.
Larsen JP, Kvale G, Nyland H. Epidemiology of the Guillain-Barre syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985;71:43-7.
Alter M. The epidemiology of Guillain-Barre syndrome. Ann Neurol 1990;27:S7-12.
Dowling PC, Menonna JP, Cook SD. Guillain-Barre syndrome in Greater New York-New Jersey. Jama 1977;238:317-8.
Baoxun Z, Yinchang Y, Huifen H, Xiuqin L. Acute polyradiculitis (Guillain-Barre syndrome): an epidemiological study of 156 cases observed in Beijing. Ann Neurol 1981;9:S146-8.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27:S21-4
Kappas A. The porphyrias. In: Scriver C, ed. The metabolic basis of inherited disease. New York: McGraw- Hill, 1989: 1305-1365.
Torbey MT, Suarez JI, Geocadin R. Less common causes of quadraparesis and respiratory failure. In: Suarez JI ed. Neurology and Neurosurgical Critical Care. Totowa, NJ: The Humana Press; 2004:493-514
Sagar S. Toxic and metabolic Disorders. In: Samuels M, ed. Manual of neurologic therapeutics, 5th Ed. Boston: Little, Brown and co, 2005: 299-301.
Bolton CF. Critical illness polyneuropathy and myopahty. Crit Care Med 2001;29:2388-2390
de Letter MAC, Schmitz PIM, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001;29:2281-2286.
Hund EF, Fogel W, Krieger D, DeGeorgia M, Hacke
W. Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 1996;24:1328-1333
Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996;347:1579-1582
Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-1416
Schwarz J, Planck J, Briegel J, Straube A. Single-fiber electromyography, nerve conduction studies, and conventional electromyography in patients with critical- illness polyneuropathy: evidence for alesion of terminal motor axons. Muscle Nerve 1997;20:696-701
Hund E. Myopathy in critically ill patients. Crit Care Med 1999;27:2544-2547
Hund E. Critical illness polyneuropathy. Curr Opin Neurol 2001;14:649-653
Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001;248:929-934
Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and Gram- negative sepsis. Intensive Care Med 1997;23:1144-1149
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.